olmesartan medoxomil has been researched along with Inflammation in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araújo, TE; Borba, PB; da Silva, AI; de Araújo Júnior, RF; de Araújo, AA; de Souza, FH; Nogueira, AC; Saldanha, TS | 1 |
| Akizawa, T; Aoshima, Y; Hirai, Y; Honda, H; Hosaka, N; Michihata, T | 1 |
| Cui, TX; Horiuchi, M; Iwai, M; Jinno, T; Li, JM; Li, Z; Liu, HW; Ogihara, T; Rakugi, H | 1 |
| Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Kitamoto, S; Ni, W; Nishida, K; Takeshita, A; Usui, M; Zhao, Q | 1 |
| Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Nishio, M; Ohtani, T; Sakata, Y; Yamamoto, K; Yoshida, J | 1 |
| Charo, IF; Egashira, K; Hiasa, K; Inoue, S; Ishibashi, M; Ishibashi, T; Kitamoto, S; Kura, S; Ohtani, K; Sugaya, T; Takeshita, A; Tsuchihashi, M; Tsuzuki, T; Zhao, Q | 1 |
| Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Kanter, J; Lahera, V; Luño, J; Puerta, M | 1 |
| Miyazaki, M; Takai, S | 1 |
2 trial(s) available for olmesartan medoxomil and Inflammation
| Article | Year |
|---|---|
Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pressure; Female; Glycation End Products, Advanced; Humans; Hypertension, Renal; Imidazoles; Inflammation; Kidney Failure, Chronic; Lysine; Male; Olmesartan Medoxomil; Oxidative Stress; Pilot Projects; Prospective Studies; Renal Dialysis; Telmisartan; Tetrazoles; Treatment Outcome | 2012 |
Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.
Topics: Adipokines; Adiponectin; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Chronic Disease; Female; Humans; Imidazoles; Inflammation; Insulin; Insulin Resistance; Interleukin-6; Kidney Diseases; Leptin; Male; Metabolic Syndrome; Middle Aged; Olmesartan Medoxomil; Tetrazoles; Waist-Hip Ratio | 2006 |
6 other study(ies) available for olmesartan medoxomil and Inflammation
| Article | Year |
|---|---|
In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Diarrhea; Disease Models, Animal; Imidazoles; Inflammation; Interleukin-1beta; Intestinal Mucosa; Intestine, Small; Male; Methotrexate; Mucositis; Neoplasms; Olmesartan Medoxomil; Rats, Wistar; Sucrose; Tetrazoles; Tumor Necrosis Factor-alpha; Weight Loss | 2015 |
Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterial Occlusive Diseases; Azetidinecarboxylic Acid; Calcium Channel Blockers; Cell Division; Dihydropyridines; Drug Synergism; Drug Therapy, Combination; Imidazoles; Inflammation; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Olmesartan Medoxomil; Oxidative Stress; Receptor, Angiotensin, Type 1; Tetrazoles; Tunica Intima | 2004 |
Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Chemokine CCL2; Chemokines; Cytokines; Disease Progression; Gene Expression Regulation; Gene Targeting; Humans; Hyperlipoproteinemia Type II; Imidazoles; Inflammation; Inflammation Mediators; Injections, Intramuscular; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Olmesartan Medoxomil; Random Allocation; Recombinant Fusion Proteins; Sequence Deletion; Single-Blind Method; Tetrazoles | 2004 |
AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium-Binding Proteins; Calcium-Transporting ATPases; Diastole; Disease Progression; Drug Therapy, Combination; Extracellular Matrix; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Imidazoles; Inflammation; Male; Olmesartan Medoxomil; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Tetrazoles; Thiazepines; Ventricular Dysfunction, Left | 2004 |
Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Bone Marrow Transplantation; Chemokine CCL2; Chemotaxis, Leukocyte; Enzyme Inhibitors; Humans; Hypertension; Hypertrophy, Left Ventricular; Imidazoles; Inflammation; Infusion Pumps, Implantable; Male; Mice; Mice, Inbred C57BL; Monocytes; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Olmesartan Medoxomil; Pilot Projects; Radiation Chimera; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptors, CCR2; Receptors, Chemokine; Recombinant Fusion Proteins; Superoxide Dismutase; Tetrazoles; Up-Regulation | 2004 |
Anti-atherosclerotic efficacy of olmesartan.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arteriosclerosis; Biomarkers; Cholesterol; Cholesterol, Dietary; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Imidazoles; In Vitro Techniques; Inflammation; Lipids; Macaca fascicularis; Male; Olmesartan Medoxomil; Tetrazoles; Treatment Outcome | 2002 |